Does hydroxyzine effectively reduce racing thoughts, and does propranolol effectively alleviate somatic symptoms of anxiety?

Hydroxyzine and Propranolol for Anxiety: Addressing Racing Thoughts and Somatic Symptoms

Neither hydroxyzine nor propranolol are first-line treatments for anxiety disorders, and the evidence does not strongly support hydroxyzine specifically for racing thoughts or propranolol for general somatic anxiety symptoms. The most recent guidelines recommend SSRIs (paroxetine, sertraline, escitalopram) or SNRIs (venlafaxine) as first-line pharmacotherapy for anxiety disorders 1.

Hydroxyzine for Racing Thoughts

The evidence for hydroxyzine does not specifically address "racing thoughts" as a target symptom. The FDA label indicates hydroxyzine is approved for "symptomatic relief of anxiety and tension associated with psychoneurosis" 2, but racing thoughts (a cognitive symptom often associated with anxiety or mood disorders) are not mentioned as a specific indication.

What hydroxyzine actually does:

• Hydroxyzine demonstrated efficacy for generalized anxiety disorder with improvement in overall anxiety measures, particularly showing early effects on a "cognitive component of anxiety" 3
• A 3-month trial showed superiority over placebo with HAM-A score improvements 4
• However, a Cochrane review concluded that due to high risk of bias in studies, small sample sizes, and limited evidence, hydroxyzine cannot be recommended as a reliable first-line treatment in GAD 5

Critical limitation: One experimental study found that single-dose hydroxyzine (25 mg) showed no significant anxiolytic effects on subjective anxiety measures in a CO2-induced anxiety model, with a trend toward higher anxiety scores than placebo 6. This raises questions about its acute efficacy.

Propranolol for Somatic Symptoms

The evidence for propranolol is more nuanced and context-dependent:

Where propranolol may work:

• A 1974 study found propranolol was more effective than placebo specifically in patients with predominantly somatic anxiety (bodily symptoms), but not effective in patients with primarily psychic/psychological anxiety 7
• Propranolol is effective for performance anxiety (fear of public speaking, specific situational phobias) at doses of 20-40 mg 8, 9
• Long-term use (up to 10 years in some patients) at 80-320 mg daily showed relief of both somatic and psychic symptoms, though this was not a controlled trial 10

Where propranolol does NOT work:

• A 2016 systematic review and meta-analysis found insufficient evidence to support routine use of propranolol for any anxiety disorder including panic disorder, social phobia, specific phobia, or PTSD 11
• The same experimental study that tested hydroxyzine found propranolol (40 mg) had no anxiolytic effect on subjective anxiety, despite significantly reducing heart rate—suggesting the anxiety response to CO2 is centrally mediated and not simply due to peripheral autonomic symptoms 6
• Benefits are limited to performance anxiety only 9

Clinical Algorithm

For generalized anxiety with cognitive symptoms (including racing thoughts):

1. First-line: SSRI (escitalopram, paroxetine, sertraline) or SNRI (venlafaxine) 1
2. Second-line: Buspirone, benzodiazepines (short-term only), or gabapentinoids
3. Hydroxyzine may be considered as an alternative if first-line agents fail, but expect modest benefits and significant drowsiness 2, 4

For performance anxiety (specific, situational):

1. Propranolol 20-40 mg taken 30-60 minutes before the performance 8, 9
2. This is the ONE clear indication where propranolol has demonstrated benefit

For somatic anxiety symptoms (palpitations, tremor, sweating) in GAD:

1. First-line: Still SSRIs/SNRIs—they treat both psychological and somatic symptoms 1
2. Propranolol may provide adjunctive benefit for peripheral somatic symptoms, but evidence is weak for chronic use 11
3. Consider if patient has predominantly somatic presentation and has failed first-line agents 7

Important Caveats

Hydroxyzine warnings:

• Causes significant drowsiness—warn against driving or operating machinery 2
• Risk of QT prolongation, especially with other QT-prolonging drugs or in patients with cardiac risk factors 2
• Can cause acute generalized exanthematous pustulosis (AGEP)—discontinue if rash develops 2
• Efficacy beyond 4 months has not been established 2

Propranolol limitations:

• Contraindicated in asthma, heart block, bradycardia, uncompensated heart failure
• May mask hypoglycemia symptoms in diabetics
• Can cause depression in predisposed patients 8
• The disconnect between heart rate reduction and lack of subjective anxiety relief suggests limited utility for central anxiety symptoms 6

Bottom line: Your statement is partially correct but oversimplified. Propranolol has a narrow role in performance anxiety only. Hydroxyzine is not specifically effective for racing thoughts and is at best a second- or third-line option for general anxiety. Both are inferior to SSRIs/SNRIs for most anxiety presentations.